Published in Acta Oncol on January 01, 2003
Tumour regression in the randomized Stockholm III Trial of radiotherapy regimens for rectal cancer. Br J Surg (2015) 1.69
Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition. Radiat Oncol (2006) 1.13
Colorectal cancer survival in the USA and Europe: a CONCORD high-resolution study. BMJ Open (2013) 1.10
Early changes in apparent diffusion coefficient predict the quantitative antitumoral activity of capecitabine, oxaliplatin, and irradiation in HT29 xenografts in athymic nude mice. Neoplasia (2007) 1.08
Neo-adjuvant radiotherapy in rectal cancer. World J Gastroenterol (2013) 0.92
Management of recurrent rectal cancer: a population based study in greater Amsterdam. World J Gastroenterol (2008) 0.91
Functional results after radiochemotherapy and total mesorectal excision for rectal cancer. Int J Colorectal Dis (2007) 0.91
The influence of AKT isoforms on radiation sensitivity and DNA repair in colon cancer cell lines. Tumour Biol (2013) 0.89
The mesorectum: morphometric assessment with magnetic resonance imaging. Eur Radiol (2005) 0.89
Matrix metalloproteinases in rectal mucosa, tumour and plasma: response after preoperative irradiation. Int J Colorectal Dis (2006) 0.85
Neoadjuvant chemoradiotherapy for rectal carcinoma: effects on anastomotic leak rate and postoperative bladder dysfunction after non-emergency sphincter-preserving anterior rectal resection. Results of the Quality Assurance in Rectal Cancer Surgery multicenter observational trial. Langenbecks Arch Surg (2010) 0.83
CPT-11 and concomitant hyperfractionated accelerated radiotherapy induce efficient local control in rectal cancer patients: results from a phase II. Br J Cancer (2006) 0.82
Upfront systemic chemotherapy and preoperative short-course radiotherapy with delayed surgery for locally advanced rectal cancer with distant metastases. Radiat Oncol (2011) 0.81
Prognostic factors associated with locally recurrent rectal cancer following primary surgery (Review). Oncol Lett (2013) 0.81
Radiotherapy: Preoperative chemoradiotherapy for rectal cancer. Nat Rev Clin Oncol (2010) 0.80
Radiotherapy response in microsatellite instability related rectal cancer. Korean J Pathol (2013) 0.80
Magnetic resonance imaging (MRI)-based indication for neoadjuvant treatment of rectal carcinoma and the surrogate endpoint CRM status. Int J Colorectal Dis (2008) 0.80
FXYD-3 expression in relation to local recurrence of rectal cancer. Radiat Oncol J (2016) 0.80
In the era of total mesorectal excision: adjuvant radiotherapy may be unnecessary for pT3N0 rectal cancer. Radiat Oncol (2014) 0.80
Current treatment of rectal cancer adapted to the individual patient. Rep Pract Oncol Radiother (2013) 0.79
Update on advances and controversy in rectal cancer treatment. Tech Coloproctol (2016) 0.78
Sphincter-preserving R0 total mesorectal excision with resection of internal genitalia combined with pre- or postoperative chemoradiation for T4 rectal cancer in females. World J Gastroenterol (2007) 0.77
Proctocolectomy for colorectal cancer--is the ileal pouch anal anastomosis a safe alternative to permanent ileostomy? Int J Colorectal Dis (2014) 0.76
Optimised surgery (so-called TME surgery) and high-resolution MRI in the planning of treatment of rectal carcinoma. Langenbecks Arch Surg (2007) 0.76
Clinical application of multimodality imaging in radiotherapy treatment planning for rectal cancer. Cancer Imaging (2013) 0.75
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Cumulative association of five genetic variants with prostate cancer. N Engl J Med (2008) 15.34
Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 9.08
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med (2014) 6.89
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85
GWAS of 126,559 individuals identifies genetic variants associated with educational attainment. Science (2013) 4.71
Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet (2013) 3.25
Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet (2008) 3.14
Sex-stratified genome-wide association studies including 270,000 individuals show sexual dimorphism in genetic loci for anthropometric traits. PLoS Genet (2013) 2.83
FTO genotype is associated with phenotypic variability of body mass index. Nature (2012) 2.77
Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study. Lancet (2002) 2.72
Polygenic risk score improves prostate cancer risk prediction: results from the Stockholm-1 cohort study. Eur Urol (2011) 2.62
Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet (2011) 2.51
Sequence variants at 22q13 are associated with prostate cancer risk. Cancer Res (2009) 2.27
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol (2007) 2.21
HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet (2012) 2.18
The mutational landscape of prostate cancer. Eur Urol (2013) 2.14
Risk of renal cell carcinoma after hysterectomy. Arch Intern Med (2010) 2.12
Estimation of absolute risk for prostate cancer using genetic markers and family history. Prostate (2009) 1.99
The prevalence of lithium-associated hyperparathyroidism in a large Swedish population attending psychiatric outpatient units. J Clin Psychopharmacol (2015) 1.98
Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden Study. Cancer Res (2004) 1.91
Familial concordance in cancer survival: a Swedish population-based study. Lancet Oncol (2007) 1.90
Fine mapping association study and functional analysis implicate a SNP in MSMB at 10q11 as a causal variant for prostate cancer risk. Hum Mol Genet (2009) 1.90
A systematic overview of radiation therapy effects in soft tissue sarcomas. Acta Oncol (2003) 1.84
Two independent prostate cancer risk-associated Loci at 11q13. Cancer Epidemiol Biomarkers Prev (2009) 1.78
SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol (2006) 1.76
Association of prostate cancer risk variants with clinicopathologic characteristics of the disease. Clin Cancer Res (2008) 1.74
Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics. Hum Genet (2006) 1.70
Women with Saethre-Chotzen syndrome are at increased risk of breast cancer. Genes Chromosomes Cancer (2007) 1.66
Risk of birth abnormalities in the offspring of men with a history of cancer: a cohort study using Danish and Swedish national registries. J Natl Cancer Inst (2011) 1.63
Causes of death in the Sami population of Sweden, 1961-2000. Int J Epidemiol (2005) 1.60
Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins. Eur Urol (2012) 1.60
Inherited genetic variant predisposes to aggressive but not indolent prostate cancer. Proc Natl Acad Sci U S A (2010) 1.59
Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J Natl Cancer Inst (2005) 1.55
A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk. Eur Urol (2012) 1.55
Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations. Prostate (2008) 1.53
Macrophage inhibitory cytokine 1: a new prognostic marker in prostate cancer. Clin Cancer Res (2009) 1.51
A novel prostate cancer susceptibility locus at 19q13. Cancer Res (2009) 1.49
A support vector machine approach for detecting gene-gene interaction. Genet Epidemiol (2008) 1.46
Gene expression profiling indicates that immunohistochemical expression of CD40 is a marker of an inflammatory reaction in the tumor stroma of diffuse large B-cell lymphoma. Leuk Lymphoma (2012) 1.43
The interaction of four genes in the inflammation pathway significantly predicts prostate cancer risk. Cancer Epidemiol Biomarkers Prev (2005) 1.39
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol (2007) 1.37
Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer. Cancer Prev Res (Phila) (2010) 1.35
Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood (2003) 1.33
Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer. Prostate (2009) 1.33
Genetic analysis of the RNASEL gene in hereditary, familial, and sporadic prostate cancer. Clin Cancer Res (2004) 1.32
Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol (2005) 1.31
Macrophage inhibitory cytokine-1 (MIC-1/GDF15): a new marker of all-cause mortality. Aging Cell (2010) 1.29
Association of a germ-line copy number variation at 2p24.3 and risk for aggressive prostate cancer. Cancer Res (2009) 1.29
Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality. Cancer Epidemiol Biomarkers Prev (2011) 1.28
Growth hormone deficiency predicts cardiovascular risk in young adults treated for acute lymphoblastic leukemia in childhood. J Clin Endocrinol Metab (2004) 1.28
H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer. J Natl Cancer Inst (2004) 1.26
Genetic markers associated with early cancer-specific mortality following prostatectomy. Cancer (2013) 1.25
Established prostate cancer susceptibility variants are not associated with disease outcome. Cancer Epidemiol Biomarkers Prev (2009) 1.24
Association between sequence variants at 17q12 and 17q24.3 and prostate cancer risk in European and African Americans. Prostate (2008) 1.24
Interaction between single nucleotide polymorphisms in selenoprotein P and mitochondrial superoxide dismutase determines prostate cancer risk. Cancer Res (2008) 1.22
Familial brain tumours-genetics or environment? A nationwide cohort study of cancer risk in spouses and first-degree relatives of brain tumour patients. Int J Cancer (2003) 1.21
Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancer. Prostate (2010) 1.20
Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics. Hum Mol Genet (2007) 1.20
Systematic replication study of reported genetic associations in prostate cancer: Strong support for genetic variation in the androgen pathway. Prostate (2006) 1.19
A systematic overview of radiation therapy effects in skeletal metastases. Acta Oncol (2003) 1.18
Fine mapping of a region of chromosome 11q13 reveals multiple independent loci associated with risk of prostate cancer. Hum Mol Genet (2011) 1.17
Association of frequent consumption of fatty fish with prostate cancer risk is modified by COX-2 polymorphism. Int J Cancer (2007) 1.15
Genome-wide scan of Swedish families with hereditary prostate cancer: suggestive evidence of linkage at 5q11.2 and 19p13.3. Prostate (2003) 1.15
A comprehensive association study for genes in inflammation pathway provides support for their roles in prostate cancer risk in the CAPS study. Prostate (2006) 1.15
Ovarian cancer linked to Lynch syndrome typically presents as early-onset, non-serous epithelial tumors. Gynecol Oncol (2011) 1.14
Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta Oncol (2005) 1.13
The mitochondrial and autosomal mutation landscapes of prostate cancer. Eur Urol (2012) 1.12
Clinical characterization and the mutation spectrum in Swedish adenomatous polyposis families. BMC Med (2008) 1.12
Interactions of sequence variants in interleukin-1 receptor-associated kinase4 and the toll-like receptor 6-1-10 gene cluster increase prostate cancer risk. Cancer Epidemiol Biomarkers Prev (2006) 1.10
The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer. J Clin Oncol (2007) 1.10
Genetic variants and family history predict prostate cancer similar to prostate-specific antigen. Clin Cancer Res (2009) 1.09
Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: results from a randomized trial. J Natl Cancer Inst (2005) 1.09
Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy. Clin Cancer Res (2014) 1.08
NordicDB: a Nordic pool and portal for genome-wide control data. Eur J Hum Genet (2010) 1.07
A systematic overview of radiation therapy effects in head and neck cancer. Acta Oncol (2003) 1.07
Implications for prostate cancer of insulin-like growth factor-I (IGF-I) genetic variation and circulating IGF-I levels. J Clin Endocrinol Metab (2007) 1.06
Evaluation of association of HNF1B variants with diverse cancers: collaborative analysis of data from 19 genome-wide association studies. PLoS One (2010) 1.05
The genetic structure of the Swedish population. PLoS One (2011) 1.05
Sequence variants in the TLR4 and TLR6-1-10 genes and prostate cancer risk. Results based on pooled analysis from three independent studies. Cancer Epidemiol Biomarkers Prev (2010) 1.05
Dietary phytoestrogen, serum enterolactone and risk of prostate cancer: the cancer prostate Sweden study (Sweden). Cancer Causes Control (2006) 1.05
[That everything gets better just because it is centralized is not an axiom]. Lakartidningen (2006) 1.04
A systematic overview of radiation therapy effects in non-Hodgkin's lymphoma. Acta Oncol (2003) 1.00
Genetic variability in inflammation pathways and prostate cancer risk. Urol Oncol (2007) 1.00
Refining the prostate cancer genetic association within the JAZF1 gene on chromosome 7p15.2. Cancer Epidemiol Biomarkers Prev (2010) 0.99
Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian Testicular Cancer Group. J Clin Oncol (2011) 0.99
Breast cancer as a second primary in patients with prostate cancer--estrogen treatment or association with family history of cancer? J Urol (2006) 0.99
Different aetiology of familial low-grade and high-grade glioma? A nationwide cohort study of familial glioma. Neuroepidemiology (2002) 0.99
Toward next generation plasma profiling via heat-induced epitope retrieval and array-based assays. Mol Cell Proteomics (2010) 0.99
Toll-like receptor signaling pathway variants and prostate cancer mortality. Cancer Epidemiol Biomarkers Prev (2009) 0.99
Estrogen receptor beta polymorphism is associated with prostate cancer risk. Clin Cancer Res (2006) 0.99
Analysis of lipid pathway genes indicates association of sequence variation near SREBF1/TOM1L2/ATPAF2 with dementia risk. Hum Mol Genet (2010) 0.99
The UGT2B17 gene deletion is not associated with prostate cancer risk. Prostate (2008) 0.98
Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study. Clin Cancer Res (2003) 0.98